Literature DB >> 3494818

Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia.

J J Wright, D G Poplack, A Bakhshi, G Reaman, D Cole, J P Jensen, S J Korsmeyer.   

Abstract

Immunoglobulin (Ig) heavy (H) and light (L) chain gene rearrangements were used as molecular markers of clonal evolution and minimal residual disease in B cell precursor acute lymphoblastic leukemia (ALL). All leukemic episodes within individual patients shared at least one identical Ig rearrangement and thus arose from a common clonal progenitor cell. Nine of 11 patients displayed completely identical patterns between leukemic episodes, while two of 11 patients demonstrated genetic progression between diagnosis and relapse as evidenced by additional rearrangements. These genetic changes marked the emergence of leukemic subclones. Ig gene rearrangements were also used as sensitive markers to identify clonal cell populations in ALL patients following induction or reinduction therapy and to search for residual bone marrow disease in patients in clinical remission or with isolated extramedullary relapse. DNA rearrangements provide tumor-specific markers to follow the genetic variation of ALL and may facilitate the early detection of recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494818     DOI: 10.1200/JCO.1987.5.5.735

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

1.  The study of minimal residual disease in acute lymphoblastic leukaemia.

Authors:  C J Knechtli; N J Goulden; K Langlands; M N Potter
Journal:  Clin Mol Pathol       Date:  1995-04

Review 2.  Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Authors:  M H Bakkus; N Juge-Morineau; J E van der Werff ten Bosch
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

3.  Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes.

Authors:  M Yamada; S Hudson; O Tournay; S Bittenbender; S S Shane; B Lange; Y Tsujimoto; A J Caton; G Rovera
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable-(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias.

Authors:  E A Macintyre; L d'Auriol; N Duparc; G Leverger; F Galibert; F Sigaux
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 5.  Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Authors:  Christopher S Hourigan; Philip McCarthy; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-27       Impact factor: 5.742

6.  Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease.

Authors:  M Crescenzi; M Seto; G P Herzig; P D Weiss; R C Griffith; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

7.  Detection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis.

Authors:  T H Davis; C E Yockey; S P Balk
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

8.  Peripheral blood involvement in non-Hodgkin's lymphoma detected by clonal gene rearrangement as a biological prognostic marker.

Authors:  L R Hiorns; J Nicholls; J P Sloane; A Horwich; S Ashley; M Brada
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

9.  Malignant cell detection in Burkitt's lymphoma using third-complementarity-determining region (CDRIII), clone-specific probe developed by sequencing DNA from stored slides.

Authors:  M Asada; T Miyashita; F Bessho; N Kobayashi; S Mizutani
Journal:  Jpn J Cancer Res       Date:  1991-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.